TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01019239

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic Washout
Description: Pneumoperitoneum will be established via a blunt entry 12mm umbilical port. Two 5mm ports will be placed in the suprapubic and right lower quadrants. The peritoneal cavity will be thoroughly examined and stage classified according to Hinchey. Peritoneal lavage will be performed in all four quadrants using at least 4 litres of warmed saline until the drainage is clear. Two non-suction Penrose drains will be placed.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hartmann's Procedure/ Primary Resection and Anastomosis
Description: 24 Pneumoperitoneum will be established via a blunt entry 12mm umbilical port. Two 5mm ports will be placed in the suprapubic and right lower quadrants to facilitate triangulation of instruments during manipulation and lavage. The peritoneal cavity will be thoroughly examined and stage classified according to Hinchey. . In the absence of faeculant peritonitis, patients will be randomised to undergo Hartmann's procedure or primary resection and anastomosis (depending on standard practice in the individual unit).
Study: NCT03379545

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: 3-dimensional (3D) magnetic resonance (MR) imaging
Description: MRI is performed using 3T scanners with a dedicated 16-channel shoulder array coils. The MRI sequences include 3-mm slice thickness and 0.5-mm gap width with a field of view of 14 or 15 cm. There were 6 diagnostic sequences with axial, coronal, and sagittal proton density weighting as well as coronal T2 with frequency selective fat suppression and sagittal T1 images.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: 3D computed tomography (CT) imaging
Description: The CT protocol consists of 3-mm axial images of the glenoid reconstructed into 1-mm sagittal and coronal 2D reconstructions using the following parameters: 120 kV, 280 mA, and pitch of 0.9. The CT data were also used to produce a 3D reconstruction of each glenoid.
Study: NCT01053247

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0416
Description: Topical 0416 test product applied twice daily for 2 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle of 0416 test product
Description: Vehicle of 0416 test product applied twice daily for 2 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tacrolimus ointment 0.1%
Description: Reference Product for 0416 test product. Apply twice daily for 2 weeks.
Study: NCT03575949

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo FDG PET/CT

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fludeoxyglucose F-18
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo FDG PET/CT
Study: NCT00823485

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: fibrinolysis in situ
Description: intraventricular injection of actilyse

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: drainage
Description: drainage
Study: NCT03554720

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ATTUNE PS Knee
Description: The ATTUNE PS Knee is the standard implants.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ATTUNE S+ PS Knee
Description: The ATTUNE S+ PS Knee is the enhanced fixation.
Study: NCT03927898

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: Participants receive Toripalimab (240mg)/q3w till progression of disease after SBRT

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiotherapy
Description: Participants receive SBRT (BED\>80Gy) to oligometastatic lesions followed by Toripalimab (240mg)/q3w
Study: NCT03055169

Intervention type: GENETIC
Intervention: genetic analysis

Intervention type: BIOLOGICAL
Intervention: blood and stools samples
Study: NCT03683537

Intervention type: DIAGNOSTIC_TEST
Intervention: Glial fibrillary acidic protein
Description: 3 samples of serum are drawn from patients. The 1st Sample of patient serum is drawn before induction into anesthesia. The 2nd is drawn 24 hours after the 1st one. The 3rd sample is drawn on 3 or 4 postoperative day. All samples collected and preserved in the same temperature as required for ELISA.

Intervention type: DIAGNOSTIC_TEST
Intervention: Glial fibrillary acidic protein
Description: 3 samples of serum are drawn from patients. The 1st Sample of patient serum is drawn before induction into anesthesia. The 2nd is drawn 24 hours after the 1st one. The 3rd sample is drawn on 3 or 4 postoperative day. All samples collected and preserved in the same temperature as required for ELISA.
Study: NCT04403542

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Lehfilcon A contact lens
Description: Investigational silicone hydrogel contact lens
Study: NCT01439490

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FES-PET
Description: Patients undergo FES-PET prior to obtaining histology
Study: NCT00547417

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tadalafil
Description: 20 mg tadalafil tablet taken by mouth, as needed, no more than once a day, for 12 weeks.
Study: NCT04403542

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lehfilcon A contact lens
Description: Investigational silicone hydrogel contact lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Comfilcon A contact lens
Description: Commercially available silicone hydrogel contact lens

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Comfilcon A contact lens
Description: Commercially available silicone hydrogel contact lens
Study: NCT04930497

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: vestibular socket technique with bone grafting
Description: a vestibular horizontal incision was made then a subperiosteal tunnel was created and a facial bone membrane was placed. The facial gap was filled with a mixture of autogenous bone and deproteinized bovine bone mineral

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: vestibular socket technique without bone grafting
Description: the vestibular incision was done horizontally about 3 to 4 mm apical to the mucogingival junction and extending 5 to 10 mm horizontally. A submucoperiosteal tunnel was created labially from the socket orifice till the vestibular access incision
Study: NCT02772328

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer Mentor
Description: comparison of communication training to equal attention control
Study: NCT00749242

Intervention type: OTHER
Group type: OTHER
Intervention: orthopedic brace
Description: antalgic drugs and orthopedic brace

Intervention type: DEVICE
Group type: OTHER
Intervention: balloon kyphoplasty
Description: introduction of balloon into the vertebral body, inflation of the balloon which creates a cavity, then balloon is deflated and removed , then introduction of the cement into the cavity.
Study: NCT01235000

Intervention type: BIOLOGICAL
Intervention: 2010-11 trivalent inactivated influenza vaccine
Description: A single age-appropriate dose of 2010-11 trivalent inactivated influenza vaccine
Study: NCT01333553

Intervention type: DEVICE
Intervention: Image-guided remove Port Wine Stain
Description: Image-guided surgery remove Port Wine Stain
Study: NCT03006185

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ablative Fractional Carbon Dioxide (CO2) Laser
Description: One 50 cm2 test area was randomized to pretreatment using a fractional 2940 nm Er:YAG laser (Joule®; Sciton Inc., Palo Alto, CA, USA). To remove hyperkeratosis, a fully-ablative 4 mm handpiece was optionally applied, followed by a single pass of a fractional Profrax 430 handpiece for all AKs. Subsequent field treatment consisted of a single pass of the Profrax 430 handpiece over the entire test area. Immediately after pretreatment, a 0.5 mm layer of methyl aminolevulinate (Metvix ® cream 16%; Galderma, Paris, France) was applied. After 30 minutes, patients were exposed to 2 hours of ambient daylight, according to approved procedure. After light exposure, cream was wiped off and test areas were covered for the remainder of the day.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Microdermabrasion
Description: Another adjacent 50 cm2 test area was exposed to microdermabrasion using an MD pad with 58.5 µm-diameter particles (Ambu® Skin Prep Pads 2121M; Ambu A/S, Ballerup, Denmark). Lesion-directed treatment consisted of an increasing number of swipes concentrated to AK lesions. During field treatment, multiple swipes were applied in perpendicular directions over the entire test area. Immediately after pretreatment, a 0.5 mm layer of methyl aminolevulinate (Metvix ® cream 16%; Galderma, Paris, France) was applied. After 30 minutes, patients were exposed to 2 hours of ambient daylight, according to approved procedure. After light exposure, cream was wiped off and test areas were covered for the remainder of the day.
Study: NCT02234947

Intervention type: PROCEDURE
Intervention: MRI, US, and blood samples
Description: All groups will have pancreatic volume assessment by ultrasonography (US), Magnetic Resonance Imaging (MRI) and blood samples. These test will be compared to the testing from the other groups.

Intervention type: PROCEDURE
Intervention: MRI, US, and blood samples
Description: All groups will have pancreatic volume assessment by ultrasonography (US), Magnetic Resonance Imaging (MRI) and blood samples. These test will be compared to the testing from the other groups.

Intervention type: PROCEDURE
Intervention: MRI, US, and blood samples
Description: All groups will have pancreatic volume assessment by ultrasonography (US), Magnetic Resonance Imaging (MRI) and blood samples. These test will be compared to the testing from the other groups.

Intervention type: PROCEDURE
Intervention: MRI, US, and blood samples
Description: All groups will have pancreatic volume assessment by ultrasonography (US), Magnetic Resonance Imaging (MRI) and blood samples. These test will be compared to the testing from the other groups.
Study: NCT00590564

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sho-saiko-to
Description: All patients will receive treatment with 2.5grams of SST as granules in packet form by mouth three times a day every day for 52 weeks unless occurrence of unacceptable adverse events or patient withdrawal. Patients will be seen for clinical follow-up at three month intervals: at 3, 6, 9, and 12 months, and assessed for compliance and asked about side effects and pulmonary symptoms. At each clinic visit, a comprehensive metabolic profile will be performed. At the 6-month clinic visit, a CBC will be performed. At the 12-month clinic visit, quantitative HCV-RNA by PCR will be obtained (Viromed Labs, Inc., 6101 Blue Circle Drive, Minneapolis, MN 5534). Within 4 weeks after the 12-month clinic visit (after 52 weeks of SST therapy), the second liver biopsy will be scheduled and performed.
Study: NCT00925392

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doripenem
Description: Intravenous 500 mg every (q) 8 hours for 3 doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doripenem
Description: Intravenous 1000 mg q 8 hours for 3 doses
Study: NCT01434680

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MenC-CRM LIQ
Description: One dose of MenC-CRM vaccine, liquid formulation

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MenC-CRM ROS
Description: One dose of MenC-CRM vaccine, lyophilized formulation produced with drug substance manufactured at Rosia, Italy.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MenC-CRM EMV
Description: One dose of MenC-CRM vaccine, lyophilized formulation produced with drug substance manufactured at Emeryville, USA.
Study: NCT03167151

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Solution for Infusion (Intravesical and Intravenous) 100mg/ 4ml vial

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: Solution for Infusion (Intravesical and Intravenous) 100mg/ 4ml vial
Study: NCT01758679

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Licartin and CIK
Description: Licartin and CIK
Study: NCT02098447

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PrimeStim
Study: NCT04374747

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietary Counseling
Description: The counseling approach will employ strategies shown to be successful in previous and ongoing dietary modification studies including supportive and motivational interviewing techniques. Each woman in the diet intervention group will be assigned a trained nutrition coach/counselor. Counselors will focus on helping participants identify and address barriers to achieving the goal of consuming at least 8 to 10 servings of nutrient dense fruits and vegetables each day (e.g., modifying recipes and food preparation). Participants will also receive weekly boxes of fruits and vegetables .
Study: NCT05276271

Intervention type: DIAGNOSTIC_TEST
Intervention: the blood sample test results
Description: Retrospectively the fasting blood samples results were obtained for serum thyroid-stimulating hormone (TSH), free triiodothyronine, free thyroxine, total cholesterol (TC), high-density lipoprotein (HDL), low-density lipoprotein (LDL), triglycerides, Triglyceride/HDL Index, uric acid, CRP, and transaminases at the administration.

Intervention type: DIAGNOSTIC_TEST
Intervention: the blood sample test results
Description: Retrospectively the fasting blood samples results were obtained for serum thyroid-stimulating hormone (TSH), free triiodothyronine, free thyroxine, total cholesterol (TC), high-density lipoprotein (HDL), low-density lipoprotein (LDL), triglycerides, Triglyceride/HDL Index, uric acid, CRP, and transaminases at the administration.
Study: NCT00990951

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Senna alexandrina and associations
Description: Drugs: Senna alexandrina Mill (sena), Cassia fistula L., Tamarindus indica L., Coriandrum sativum L., Periandra mediterranea Taub~1 tablet PO twice a day
Study: NCT03102489

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BP101
Description: Nasal spray

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Nasal spray
Study: NCT03550469

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Computer-assisted Oxygen Weaning
Description: Oxygen therapy weaning will be guided by a model-based computer algorithm. The computer will detect patients' oxygen saturation and made recommendations for oxygen weaning. A clinical at the bedside will make the adjustments in oxygen therapy if appropriate.
Study: NCT02320526

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Continuous walking

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interval walking
Study: NCT02763215

Intervention type: DRUG
Intervention: Standard of Care Medications
Description: Standard of care medications could include penicillamine, trientine, zinc, or a combination of a copper chelator and zinc.
Study: NCT00903825

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound guided injection of femoral local anesthetic (lidocaine)
Description: Injection of lidocaine (\< 10 mls of lidocaine, 1%w/v) before femoral artery puncture with free-hand duplex ultrasound guidance.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Injection of femoral local anesthetic (lidocaine) with manual palpation
Description: Injection of lidocaine before femoral artery catheterization with manual palpation.
Study: NCT00942747

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temsirolimus
Description: Weekly infusion of 25mg Temsirolimus (first 3 patients) or 75mg Temsirolimus (all other patients) up to a maximum of 12 months in the case of continuing response to treatment
Study: NCT04663477

Intervention type: DIAGNOSTIC_TEST
Intervention: patient-completed Caprini Risk Score
Description: The participants will be asked to complete patient-completed Caprini Risk Score

Intervention type: DIAGNOSTIC_TEST
Intervention: patient-completed Caprini Risk Score
Description: The participants will be asked to complete patient-completed Caprini Risk Score
Study: NCT01155414

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hydrolysate based infant formula
Description: Infant formula ad lib

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Investigational Infant Formula A
Description: Investigational infant formula ad lib

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Investigational Infant Formula B
Description: Investigational infant formula ad lib
Study: NCT04395170

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: COVID-19 convalescent plasma
Description: Plasma from convalescent patients with COVID-19 and at the same time receiving supportive therapy, with inactivation / reduction of pathogens, in the scheme of two doses of 200 - 250 mL administered on days 1 and 3 of the intervention.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-COVID-19 human immunoglobulin
Description: Anti-COVID-19 human immunoglobulin produced by Lifefactors Zona Franca S.A.S, intravenously at a dose of immunoglobulin 10% IgG solution (10% mL vial) for:~Patient of 50 Kg or more, a dose of 50 mL, administered on days 1 and 3 of treatment.~Patient under 50 Kg, the dose will be 1 mL / Kg, administered on days 1 and 3 of treatment.~The supply of anti-COVID-19 human immunoglobulin produced by Lifefactors Zona Franca S.A.S included once it has been authorized by INVIMA and/or the regulatory requirements in force for the production of drugs are met.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard (specific) therapy for COVID-19
Description: Standard therapy for COVID-19 according to the recommended pharmacological recommendations of the Colombian Association of Infectious Diseases - ACIN. This therapy is subject to changes that are defined by the Colombian Health Regulatory Authorities.~To date, these therapies may include remdesivir, chloroquine, hydroxychloroquine, azithromycin.
Study: NCT01976273

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 1064nm Q-switch Laser

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Glycolic Acid Peels
Study: NCT02525692

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dordaviprone (ONC201)
Description: Dordaviprone (ONC201) is a brain-penetrant, small-molecule imipridone that acts as a mitochondrial caseinolytic protease P (ClpP) agonist and a dopamine receptor D2 (DRD2) antagonist.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dordaviprone (ONC201)
Description: Dordaviprone (ONC201) is a brain-penetrant, small-molecule imipridone that acts as a mitochondrial caseinolytic protease P (ClpP) agonist and a dopamine receptor D2 (DRD2) antagonist.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dordaviprone (ONC201)
Description: Dordaviprone (ONC201) is a brain-penetrant, small-molecule imipridone that acts as a mitochondrial caseinolytic protease P (ClpP) agonist and a dopamine receptor D2 (DRD2) antagonist.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dordaviprone (ONC201)
Description: Dordaviprone (ONC201) is a brain-penetrant, small-molecule imipridone that acts as a mitochondrial caseinolytic protease P (ClpP) agonist and a dopamine receptor D2 (DRD2) antagonist.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dordaviprone (ONC201)
Description: Dordaviprone (ONC201) is a brain-penetrant, small-molecule imipridone that acts as a mitochondrial caseinolytic protease P (ClpP) agonist and a dopamine receptor D2 (DRD2) antagonist.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dordaviprone (ONC201)
Description: Dordaviprone (ONC201) is a brain-penetrant, small-molecule imipridone that acts as a mitochondrial caseinolytic protease P (ClpP) agonist and a dopamine receptor D2 (DRD2) antagonist.
Study: NCT01174446

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BAX 326
Description: * Study Part 1: Pharmacokinetic (PK) Crossover with BAX326 and BeneFIX~* Study Part 2: Open-label evaluation of prophylaxis and on-demand BAX326 only~* Study Part 3: Open-label repeat of PK evaluation (repeat Study Part 1) with BAX326 only and same study participants as Study Part 1

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: BeneFIX
Description: * Study Part 1: Pharmacokinetic (PK) Crossover with BAX326 and BeneFIX.~* BeneFIX only used in Part 1 of this study.~* Study Part 2 and 3 only utilized BAX326
Study: NCT03049670

Intervention type: DEVICE
Intervention: latent available chlorine (LAC)
Description: local application on the necrotic infected tissue
Study: NCT03034850

Intervention type: PROCEDURE
Intervention: CRS/HIPEC
Description: The generic surgical approach involved peritonectomy procedures and visceral resections called CRS as described by Sugarbaker (1995). Peritoneal disease burden was assessed using the perito- neal cancer index (PCI), which scores 13 intra-abdominal sites on a scale of 0 (no disease) to 3 (lesion size \> 5 cm), thus giving a range of possible scores from 0 to 39. The same team performed the surgical procedure of all included patients. Before connection to the patient, the circuit was filled with dextrose 5% (2 L/m2 body surface area) and warmed to 37°C.
Study: NCT02939846

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: Trametinib study will be provided as 0.5 mg and 2.0 mg tablets. Each tablet will contain 0.5 mg or 2.0 mg of trametinib parent (present as the DMSO solvate)
Study: NCT02083601

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Parent Forum
Description: In-person psychoeducational workshop that provides education (including problem-solving training) and psychological/peer support for caregivers of youth with SCI.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parent Forum
Description: In-person psychoeducational workshop that provides education (including problem-solving training) and psychological/peer support for caregivers of youth with SCI.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychological support
Description: Outreach from a mental health professional in the form of monthly phone calls for 12 months.
Study: NCT01808131

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lesinurad
Description: Tablets, 200 mg QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lesinurad
Description: Tablets, 400 mg QD
Study: NCT03113383

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Thoracoabdominal Aortic Aneurysm Repair
Description: Thoracoabdominal aortic aneurysm repair

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Thoracoabdominal Aortic Aneurysm Repair
Description: Thoracoabdominal aortic aneurysm repair
Study: NCT02339623

Intervention type: DEVICE
Intervention: Ultrasound imaging
Description: 1. - Fetal adrenal gland volume calculation using 3D ultrasound~2. - Assessment of the fetal central adrenal zone enlargement by 3D ultrasound~3. - CL measurement using 2D ultrasound